Gemtuzumab Ozogamicin represents a unique development in the approach of relapsed myeloblastic leukemia, particularly acute blood leukemia (AML). This novel conjugate combines a targeted antibody specific for the CD33 https://www.targetmol.com/compound/gemtuzumab